Integrating Phase 2 Into Phase 3 Based on an Intermediate Endpoint While Accounting for a Cure Proportion—With an Application to the Design of a Clinical Trial in Acute Myeloid Leukemia

Pharmaceutical Statistics - United Kingdom
doi 10.1002/pst.1969
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Design of the Myechild Trial, an International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia Incorporating an Embedded Dose Finding Study

Trials
MedicinePharmacology
2015English

Applicability of a "Pick a Winner" Trial Design to Acute Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2011English

Integrating Data From an Online Diabetes Prevention Program Into an Electronic Health Record and Clinical Workflow, a Design Phase Usability Study

BMC Medical Informatics and Decision Making
Health PolicyHealth Informatics
2016English

A Phase II Study of Bortezomib in Combination With Pegylated Liposomal Doxorubicin for Acute Myeloid Leukemia

American Journal of Hematology
Hematology
2019English

A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

A Phase I Trial of Ribavirin and Low-Dose Cytarabine for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia With Elevated eIF4E

Haematologica
Hematology
2014English

Integrating Communication Into an Accounting Curriculum

Review of Business Information Systems (RBIS)
1998English

Phase 1 Study of the MDM2 Antagonist RO6839921 in Patients With Acute Myeloid Leukemia

Investigational New Drugs
OncologyPharmacology
2020English

Caring an Elderly Patient With Acute Myeloid Leukemia: A Case Study

Hemşirelikte Eğitim ve Araştırma Dergisi
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy